WO2003082893A3 - Methodes therapeutiques et utilisations des sapogenines et de leurs derives - Google Patents

Methodes therapeutiques et utilisations des sapogenines et de leurs derives Download PDF

Info

Publication number
WO2003082893A3
WO2003082893A3 PCT/GB2003/001380 GB0301380W WO03082893A3 WO 2003082893 A3 WO2003082893 A3 WO 2003082893A3 GB 0301380 W GB0301380 W GB 0301380W WO 03082893 A3 WO03082893 A3 WO 03082893A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
sapogenins
cognitive
methods
theraputic
Prior art date
Application number
PCT/GB2003/001380
Other languages
English (en)
Other versions
WO2003082893A2 (fr
WO2003082893A8 (fr
Inventor
Daryl Rees
Phil Gunning
Antonia Orsi
Zongqin Xia
Yaer Hu
Original Assignee
Phytopharm Plc
Daryl Rees
Phil Gunning
Antonia Orsi
Zongqin Xia
Yaer Hu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/es
Priority to EP03722713A priority Critical patent/EP1490071B1/fr
Priority to DE60326437T priority patent/DE60326437D1/de
Priority to KR1020047014567A priority patent/KR101130212B1/ko
Priority to AU2003229877A priority patent/AU2003229877B8/en
Priority to US10/507,000 priority patent/US20050130948A1/en
Priority to NZ535093A priority patent/NZ535093A/en
Priority to BR0308788-3A priority patent/BR0308788A/pt
Priority to IL16416103A priority patent/IL164161A0/xx
Priority to CN038071886A priority patent/CN1642558B/zh
Application filed by Phytopharm Plc, Daryl Rees, Phil Gunning, Antonia Orsi, Zongqin Xia, Yaer Hu filed Critical Phytopharm Plc
Priority to KR1020127008441A priority patent/KR20120128596A/ko
Priority to CA2477787A priority patent/CA2477787C/fr
Priority to MXPA04009321A priority patent/MXPA04009321A/es
Priority to JP2003580357A priority patent/JP4573157B2/ja
Publication of WO2003082893A2 publication Critical patent/WO2003082893A2/fr
Publication of WO2003082893A8 publication Critical patent/WO2003082893A8/fr
Publication of WO2003082893A3 publication Critical patent/WO2003082893A3/fr
Priority to NO20044468A priority patent/NO20044468L/no
Priority to HR20041009A priority patent/HRP20041009A2/xx
Priority to HK04110420.5A priority patent/HK1067546A1/xx
Priority to AU2008207565A priority patent/AU2008207565A1/en
Priority to US13/085,225 priority patent/US20110190249A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)

Abstract

L'invention concerne des méthodes thérapeutiques et les utilisations de certaines sapogénines stéroïdiques, des composés analogues et des dérivés de ce celles-ci, pour le traitement de la neurodégénérescence non cognitive, de la dégénérescence neuromusculaire non-cognitive, de la neurodégénérescence senso-motrice ou des dysfonctions ou des pertes des récepteurs, en l'absence de troubles cognitifs, neurologiques et neuromusculaires.
PCT/GB2003/001380 2002-03-27 2003-03-27 Methodes therapeutiques et utilisations des sapogenines et de leurs derives WO2003082893A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020127008441A KR20120128596A (ko) 2002-03-27 2003-03-27 사포게닌 및 그 유도체의 치료 방법 및 용도
CA2477787A CA2477787C (fr) 2002-03-27 2003-03-27 Methodes therapeutiques et utilisations des sapogenines et de leurs derives
DE60326437T DE60326437D1 (de) 2002-03-27 2003-03-27 Therapeutische verwendung von sapogeninen
AU2003229877A AU2003229877B8 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives
US10/507,000 US20050130948A1 (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
NZ535093A NZ535093A (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
BR0308788-3A BR0308788A (pt) 2002-03-27 2003-03-27 Processos terapêuticos e usos de sapogeninas e seus derivados
IL16416103A IL164161A0 (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
MXPA04009321A MXPA04009321A (es) 2002-03-27 2003-03-27 Metodos y usos terapeuticos de sapogeninas y sus derivados.
EP03722713A EP1490071B1 (fr) 2002-03-27 2003-03-27 Utilisations therapeutiques des sapogenines
JP2003580357A JP4573157B2 (ja) 2002-03-27 2003-03-27 治療方法ならびにサポゲニンおよびその誘導体の使用
KR1020047014567A KR101130212B1 (ko) 2002-03-27 2003-03-27 사포게닌 및 그 유도체의 치료 방법 및 사용법
CN038071886A CN1642558B (zh) 2002-03-27 2003-03-27 皂角苷配基及其衍生物的用途
NO20044468A NO20044468L (no) 2002-03-27 2004-10-20 Anvendelse av sapogeniner samt derav ved fremstilling av medikamenter
HR20041009A HRP20041009A2 (en) 2002-03-27 2004-10-27 Theraputic methods and uses of sapogenins and their derivatives
HK04110420.5A HK1067546A1 (en) 2002-03-27 2004-12-31 Therapeutic uses of sapogenins
AU2008207565A AU2008207565A1 (en) 2002-03-27 2008-08-27 Therapeutic methods and uses of sapogenins and their derivatives
US13/085,225 US20110190249A1 (en) 2002-03-27 2011-04-12 Therapeutic methods and uses of sapogenins and their derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ARP020101170 2002-03-27
ARP020101170A AR033079A1 (es) 2001-03-28 2002-03-27 Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P 2002-03-28 2002-03-28
US60/368,178 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (fr) 2001-03-28 2002-03-28 Derives de sapogenine, synthese et utilisation correspondantes et procedes fondes sur leur utilisation
GBPCT/GB02/01578 2002-03-28

Publications (3)

Publication Number Publication Date
WO2003082893A2 WO2003082893A2 (fr) 2003-10-09
WO2003082893A8 WO2003082893A8 (fr) 2003-12-31
WO2003082893A3 true WO2003082893A3 (fr) 2004-04-15

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001380 WO2003082893A2 (fr) 2002-03-27 2003-03-27 Methodes therapeutiques et utilisations des sapogenines et de leurs derives

Country Status (10)

Country Link
KR (1) KR20100093621A (fr)
CN (1) CN1642558B (fr)
AT (1) ATE424211T1 (fr)
IL (1) IL164161A0 (fr)
NZ (2) NZ547897A (fr)
PE (1) PE20040306A1 (fr)
PL (1) PL213697B1 (fr)
RU (1) RU2332999C2 (fr)
TW (1) TWI329016B (fr)
WO (1) WO2003082893A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (fr) * 2004-04-09 2008-09-26 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
WO2007049932A1 (fr) 2005-10-28 2007-05-03 Sun-Yeou Kim Extrait de la famille dioscoreaceae et composition le comprenant pour prevenir ou traiter la neuropathie peripherique
WO2010084356A1 (fr) 2009-01-24 2010-07-29 Phytopharm Plc Traitement de troubles médiés par un facteur neurotrophique
BR112013001422A2 (pt) * 2010-07-20 2019-09-24 Phytopharm Plc metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
WO2013149580A1 (fr) * 2012-04-03 2013-10-10 Chiming Che Composés timosaponine
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
SG10202010553XA (en) 2015-07-06 2020-12-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
CN108135911B (zh) 2015-07-06 2021-06-25 萨奇治疗股份有限公司 氧甾醇及其使用方法
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162330A1 (fr) * 1984-04-30 1985-11-27 Roecar Holdings (Netherlands Antilles) N.V. Utilisation de stérolines et de spirokétalines dans la fabrication de médicaments pour traiter le psoriasis
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
EP0659762A2 (fr) * 1993-12-24 1995-06-28 Mitsubishi Chemical Corporation Amides de l'acide sialique avec les dérivés 3-amino-sterols
JPH092956A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 神経障害の治療、予防薬
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬
WO1998002450A2 (fr) * 1996-07-11 1998-01-22 Inflazyme Pharmaceuticals Ltd. Steroides oxygenes en position 6, 7 et leurs utilisations
WO1999048507A2 (fr) * 1998-03-26 1999-09-30 Phytopharm Plc Recepteurs membranaires et leur fonction, dysfonctionnement cognitif et traitements correspondants, et compositions pour de tels traitements
EP1024146A1 (fr) * 1997-09-26 2000-08-02 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide
WO2001023407A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de sapogenine et leur utilisation dans le traitement de dysfonctionnement cognitif
WO2001023406A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence
WO2001023408A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives 5-hydroxysapogenine actifs contre la demence
WO2001049703A2 (fr) * 2000-01-06 2001-07-12 Phytopharm Plc Sapogenines substituees et leur utilisation
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
WO2003077869A2 (fr) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Compositions pharmaceutiques neuroprotectrices a base de spirostenol

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162330A1 (fr) * 1984-04-30 1985-11-27 Roecar Holdings (Netherlands Antilles) N.V. Utilisation de stérolines et de spirokétalines dans la fabrication de médicaments pour traiter le psoriasis
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
EP0659762A2 (fr) * 1993-12-24 1995-06-28 Mitsubishi Chemical Corporation Amides de l'acide sialique avec les dérivés 3-amino-sterols
JPH092956A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 神経障害の治療、予防薬
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬
WO1998002450A2 (fr) * 1996-07-11 1998-01-22 Inflazyme Pharmaceuticals Ltd. Steroides oxygenes en position 6, 7 et leurs utilisations
EP1024146A1 (fr) * 1997-09-26 2000-08-02 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide
WO1999048507A2 (fr) * 1998-03-26 1999-09-30 Phytopharm Plc Recepteurs membranaires et leur fonction, dysfonctionnement cognitif et traitements correspondants, et compositions pour de tels traitements
WO2001023407A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de sapogenine et leur utilisation dans le traitement de dysfonctionnement cognitif
WO2001023406A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence
WO2001023408A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives 5-hydroxysapogenine actifs contre la demence
WO2001049703A2 (fr) * 2000-01-06 2001-07-12 Phytopharm Plc Sapogenines substituees et leur utilisation
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
WO2003077869A2 (fr) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Compositions pharmaceutiques neuroprotectrices a base de spirostenol

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199343, Derwent World Patents Index; Class B04, AN 1993-339641, XP002157713 *
INOUE K ET AL: "Cholestanol induces apoptosis of cerebellar neuronal cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 5 MAR 1999, vol. 256, no. 1, 5 March 1999 (1999-03-05), pages 198 - 203, XP001188107, ISSN: 0006-291X *
KYOUNG SOOK KIM, ET AL.: "Effects of cholestanol feeding on corneal dystrophy in mice.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1085, 1991, pages 343 - 349, XP008027217 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05 30 May 1997 (1997-05-30) *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05 3 May 2002 (2002-05-03) *
SUN, HUI ET AL: "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease", JOURNAL OF BIOLOGICAL CHEMISTRY (1999), 274(12), 8269-8281, XP001165795 *

Also Published As

Publication number Publication date
RU2332999C2 (ru) 2008-09-10
TWI329016B (en) 2010-08-21
PE20040306A1 (es) 2004-05-29
CN1642558A (zh) 2005-07-20
PL213697B1 (pl) 2013-04-30
CN1642558B (zh) 2012-05-30
RU2004130281A (ru) 2006-01-20
WO2003082893A2 (fr) 2003-10-09
ATE424211T1 (de) 2009-03-15
KR20100093621A (ko) 2010-08-25
TW200400042A (en) 2004-01-01
WO2003082893A8 (fr) 2003-12-31
NZ547344A (en) 2007-11-30
IL164161A0 (en) 2005-12-18
PL372941A1 (en) 2005-08-08
NZ547897A (en) 2008-02-29

Similar Documents

Publication Publication Date Title
WO2003082893A8 (fr) Methodes therapeutiques et utilisations des sapogenines et de leurs derives
WO2002079221A3 (fr) Derives de sapogenine, synthese et utilisation correspondantes et procedes fondes sur leur utilisation
WO2001049703A3 (fr) Sapogenines substituees et leur utilisation
PL343508A1 (en) Smilagenin and anzurogenin-d and their use
GB9923076D0 (en) Sapogenin derivatives and their use
WO2003082208A3 (fr) Composes de pyrrolopyridazine et methodes d&#39;utilisation de ces composes pour le traitement de maladies proliferatives
CA2385410A1 (fr) Derives de sapogenine et leur utilisation dans le traitement de dysfonctionnement cognitif
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
GB9923078D0 (en) Sapogenin derivatives and their use
WO2004009064A8 (fr) Utilisation de substances neurotoxiques dans la production d&#39;un agent destine au traitement des douleurs articulaires et procede d&#39;application dudit agent
WO2005124563A3 (fr) Composes et kits de traitement de troubles musculaires et procedes d&#39;utilisation de ceux-ci
WO2004105696A3 (fr) Therapie combinatoire pour le traitement des neoplasmes
WO2004034889A3 (fr) Therapie photodynamique pour neovascularisation oculaire
HRP20041009A2 (en) Theraputic methods and uses of sapogenins and their derivatives
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives
WO2005058911A3 (fr) [1,4]oxazino[2,3-g]indazoles substitues pour traiter le glaucome
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
BR0308788A (pt) Processos terapêuticos e usos de sapogeninas e seus derivados
AU2003251734A1 (en) Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
WO2004103985A3 (fr) Synthese de chromanones
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2004073631A3 (fr) Polytherapie pour le traitement de neoplasmes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003722713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2477787

Country of ref document: CA

Ref document number: 1-2004-501326

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 535093

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 502/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020047014567

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 164161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009321

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003580357

Country of ref document: JP

Ref document number: 2003229877

Country of ref document: AU

Ref document number: 20038071886

Country of ref document: CN

Ref document number: 372941

Country of ref document: PL

ENP Entry into the national phase

Ref document number: 2004130281

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20041009A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020047014567

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003722713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10507000

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12007501847

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 196300

Country of ref document: IL